SI-BONE INC

SIBNNASDAQ

🏆 #2329 by market capUS Equity

$18.66▼ $0.11 (−0.61%)

Live

1h▲ 0.3%

24h▼ 0.6%

7d▲ 3.5%

14d▲ 1.4%

30d▲ 4.5%

1y▲ 22.6%

🏦Market Cap

$828M

Small Cap

📈Revenue Growth (YoY)

+20.2%

Healthy

📊Gross Margin

79.5%

High

💵FCF Margin

-2.0%

Thin

⚖️P/S Ratio

3.9x

Fair

Otter Score

Weak

Trading Snapshot

Day Range: $18.40 – $18.78
52-Week Range: $11.48 – $21.89
Volume: $3.33B
Avg Volume: $2.67B
Shares Outstanding: 44.3M
Next Earnings: Sep 20, 2026

Fundamentals Snapshot

Annual Revenue: $201M
Last Q Revenue: $56M
P/E Ratio: -55.3
P/S Ratio: 3.9x
EPS (TTM): $-0.33
Dividend Yield: 0.00%

Why Investors Own SIBN

✓High-growth profile — revenue up -3.1% YoY with expanding US Equity exposure.
✓Healthy economics — 71% gross margin and 7% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$201M▼ −2.0% YoY

Gross Margin (TTM)

70.9%▲ +1.3% YoY

Operating Income (TTM)

$71M▼ −2.0% YoY

Free Cash Flow (TTM)

$15M▼ −2.0% YoY

About SI-BONE INC

SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.

🦦